Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: Results of exploratory phase I/II trials in patients with metastatic melanoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 3, 2007, Pages 309-321

  Dillman, Robert O ^a   DePriest, Carol ^a   DeLeon, Cristina ^a   Barth, Neil M ^a   Schwartzberg, Lee S ^b   Beutel, Linda D ^a   Schiltz, Patric M ^a   Nayak, Shankar K ^a  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^b WEST CLINIC   (United States)

Author keywords

Active specific immunotherapy; Autologous tumor cell lines; Melanoma; Tumor stem cells; Vaccines

Indexed keywords

BCG VACCINE; CANCER VACCINE; GAMMA INTERFERON; GAMMIMMUNE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; SARGAMOSTATIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CRYOPRESERVATION; DELAYED HYPERSENSITIVITY; EXPLORATORY RESEARCH; FATIGUE; FEMALE; FEVER; FOLLOW UP; HUMAN; IRRADIATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN IRRITATION; TREATMENT RESPONSE; TUMOR CELL LINE; VACCINATION; VITILIGO;

CANCER VACCINES; CELL LINE, TUMOR; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMANS; IMMUNOTHERAPY; MAGNETIC RESONANCE SPECTROSCOPY; MELANOMA; NEOPLASM METASTASIS; PATIENT SELECTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34447519095     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.345     Document Type: Article

References (46)

1. Agarwala SS, Neuberg D, Park Y, et al. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): A trial of the Eastern Oncology Group. Cancer 2004;100:1692.
2. Kirkwood JM, Manola J, Ibrahim J, et al. Eastern Cooperative Oncology Group: A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:1670.
3. Atkins MA, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105.
4. Yanelli JR, Wroblewski JM. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. Vaccine 2004;23:97.
5. Choudhury A, Mosolits S, Kokhaei P, et al. Clinical results of vaccine therapy for cancer: Learning from history for improving the future. Adv Cancer Res 2006;95:147.
6. Morton DL, Wanek L, Nizze JA, et al. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Ann Surg 1991;214:491.
7. Livingston PO, Wong GYC, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12: 1036.
8. Berd D, Maguire HC, Jr, Schuchter LM, et al. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 1997,15:2359.
9. Hsueh EC, Nathanson L, Foshag LJ, et al. Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases. Cancer 1999;85:2160.
10. Mitchell MS, Harel W, Kempf RA, et al. Active-specific immunotherapy for melanoma. J Clin Oncol 1990;8:856.
11. Berd D, Maguire HC, Jr, McCue P, et al. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients. J Clin Oncol 1990;8:1858.
12. Morton DL, Foshag LJ, Hoon DSB, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;216:463.
13. Bystryn J-C, Zeleniuch-Jacquotte A, Oratz R, et al. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res 2001;7:1882.
14. Hersey P, Coates AS, McCarthy WH, et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: Results of a randomized trial. J Clin Oncol 2002;20:4181.
15. Hsueh EC, Morton DL. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Semin Cancer Biol 2003;13:401.
16. Richards J, Testori A, Whitman E, et al. Autologous tumor-derived HSPPC-96 versus physician's choice in a randomized phase II trial in stage IV melanoma. [abstract] J Clin Oncol 2006;24(18S):453.
17. Sondak VK, Liu PY, Tuthill RJ, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002;20:2058.
18. Wallack MK, Muthukumaran S, Balch CM, et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998;187:69.
19. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850.
20. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005;23:741.
21. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709.
22. Dillman RO, Nayak SK, Beutel L. Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J Immunother 1993;14:65.
23. Dillman RO, Beutel LD, Barth NM, et al. Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: Induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival. Cancer Biother Radiopharm 2002;17:51.
24. Nayak SK, Dillman RO. Establishment of multiple tumor cell lines from a patient with melanoma: A simple method to control fibroblast growth. Clin Biotechnol 1991;3:237.
25. Dillman RO, Nayak SK, Barth NM, et al. Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma. Cancer Biother Radiopharm 1998;13:165.
26. Dillman RO, DeLeon C, Beutel LD, et al. Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma. Crit Rev Oncol Hematol 2001;39:115
27. Nayak SK, McCallister T, Han LJ, et al. Transduction of human renal carcinoma cells with human γ-interferon gene via retroviral vector. Cancer Gene Ther 1996;3:143.
28. Nayak SK, Schiltz PM, Dillman RO. Modulation of renal carcinoma cells in vitro: comparison after transduction with retroviral vector containing a human γ-interferon gene versus incubation with soluble γ-interferon. J Interfer Cyto Res 1999;19:49.
29. Dillman RO, Crispin R, Oldham RK. The Cancer Biotherapy Research Group (CBRG), (formerly the National Biotherapy Study Group [NBSG]): A 10-year perspective. Cancer Biother Radiopharm 1997;12:229.
30. Dillman RO, Wiemann M, Nayak SK, et al. Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: A randomized phase II trial of the Cancer Biotherapy Research Group. J Immunother 2003;26:367.
31. Schiltz PM, Beutel LD, Nayak SK, et al. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer. J Immunother 1997;20:377.
32. Schiltz PM, Dillman RO. Serum cytokines in metastatic melanoma patients treated with an autologous tumor vaccine. Cancer Biother Radiopharm 2004;18:879.
33. Kaplan G, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457.
34. Lagakos SD. Statistical analysis of survival data. In: Bailar JC III, Mosteller JC, eds. Medical Uses of Statistics, 2nd ed. Boston: NEJM Books, 1992.
35. Kessler DA, Siegel JP, Hoguchi PD, et al. Regulation of somatic-cell therapy and gene therapy by the Food and Drug Administration. N Engl J Med 1993;329:1169.
36. Keilholz U, Weber J, Finke JH, et al. Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002;25:97.
37. Whiteside TL, Zhao Y, Tsukishiro T, et al. Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell response to a dendritic cell-based multipeptide vaccine inpatients with melanoma. Clin Cancer Res 2003;9:641.
38. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19: 3622.
39. Tagawa ST, Cheung E, Banta W, et al. Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with stage IV melanoma. Cancer 2006;106:1353.
40. Dillman RO, Selvan SR, Schiltz PM, et al. Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: Planned interim analysis. Cancer Biother Radiopharm 2004;19:658.
41. Dillman RO, Selvan SR, Schiltz PM. Long-term progression-free survival in metastatic melanoma following treatment with patient-specific dendritic cell vaccines. N Engl J Med 2006;355:1179.
42. Krause SW, Neumann C, Soruri A, et al. The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J Immunother 2002;25:421.
43. O'Rourke MG, Johnson M, Lanagan C, et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 2003;52:387.
44. Heresy P, Menzies SW, Halliday GM, et al. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother 2004;53:125.
45. Vilella R, Benitez D, Mila J, et al. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate. Cancer Immunol Immunother 2004;53:651.
46. Trefzer U, Herberth G, Wohlan K, et al. Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: Immunological effects and clinical results. Vaccine 2005;23:2367.